Accelerate the development of innovative tumor-targeted therapies
CAMBRIDGE, MA, May 23, 2024/PRNewswire/ -- Nona Biotech (a wholly-owned subsidiary of Harbour BioMed), a company dedicated to cutting-edge technological innovation and providing partners with ideas to IND (I to I) covering target verification and next-generation biomacromolecular drugs from discovery to pre-clinical developmentTM) A full-service international innovative biotechnology company announced today that it has reached a licensing agreement with AstraZeneca for a preclinical monoclonal antibody program to accelerate the development of targeted cancer therapies.
Under the agreement, Nona Biotech will receive a down payment of $19 million upon completion of the transaction, and is entitled to an anticipated recent milestone payment of $10 million, as well as up to $575 million in development, regulatory and commercial milestone payments and tiered royalties based on net sales. Additionally, if AstraZeneca exercises its right to choose, Nona Biotech will receive further related payments.
Dr. Wang Jinsong, Chairman of Nona Biotech, said: “We are delighted to have reached this partnership with AstraZeneca, a global leader in targeted oncology therapies to maximize the potential of our novel antibodies. This collaboration further validates the strength of Nona Biotech's leading antibody discovery platform, and we look forward to seeing Nona Biotech's innovative antibodies be developed into new anti-cancer drugs to benefit more patients.”
“This is an exciting collaboration. Based on AstraZeneca's industry-leading R&D capabilities, antibodies produced by Nona Biotech's innovative biologics discovery engine are expected to be further developed into novel tumor-targeted therapies,” said Puja Sapra, senior vice president of bioengineering and targeted oncology therapy at AstraZeneca Oncology Research and Development Division.
About Nona Biotech
Nona Biotech is an international innovative biotechnology company. As a wholly-owned subsidiary of Hebo Harbour BioMed (stock code: 02142.HK), it is committed to cutting-edge technological innovation, and provides partners with I to I covering target verification and diversified morphological drug molecules from discovery to pre-clinical developmentTM(Idea to IND) Full service. Using an integrated innovative technology platform and a team of world-leading scientists, the company provides complete antibody discovery solutions covering antigen preparation, animal immunity, single B cell screening, antibody development and engineering, pharmacogenicity evaluation, and pharmacological evaluation.
Harbour MiceIt can produce all-human monoclonal antibodies in the form of classic antibodies (H2L2) and heavy chain (HCaB) only, and cooperate with single B cell cloning screening platforms to optimize antibody discovery efficiency. Nona Biotech focuses on a global patented technology platform to enable innovation in global biomedical sources and promote the development of next-generation antibody drugs around the world. For more information, please visit
For media inquiries: pr@nonabio.com